文献速递甲状腺疾病

恩科拉非尼联合比美替尼治疗日本转移性BRAF突变甲状腺癌患者的2期研究

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
PubMed 文献 · Thyroid · 2024-03-14

这项在日本10家机构开展的2期开放标签非对照研究纳入22例BRAF V600E突变甲状腺癌患者(17例分化型,5例未分化型),评估恩科拉非尼联合比美替尼的疗效与安全性。中心评估客观缓解率为54.5%(95%CI 32.2-75.6),分化型为47.1%,未分化型为80.0%,未发现新的安全性问题。

要点

  • 中心评估客观缓解率54.5%,分化型甲状腺癌47.1%,未分化型甲状腺癌80.0%。
  • 所有患者发生至少1例不良事件,6例(27.3%)发生3级不良事件,无4-5级不良事件。
  • 最常见的3级不良事件为脂肪酶升高(4例,18.2%)。

核心结论

  • 恩科拉非尼联合比美替尼达到主要终点标准,在BRAF V600E突变甲状腺癌患者中显示临床获益,无论组织学类型为分化型或未分化型,未发现新的安全性问题。
  • 作者认为恩科拉非尼联合比美替尼可能成为BRAF V600突变甲状腺癌的新治疗选择。

研究设计与样本

  • 这是一项在日本10家机构开展的2期、开放标签、非对照研究。
  • 研究纳入BRAF V600突变局部晚期或远处转移性甲状腺癌患者,患者不适合根治性治疗,且对至少1种既往血管内皮生长因子受体靶向方案难治或不耐受,或被判定不适合该类方案。
  • 共纳入22例BRAF V600E突变甲状腺癌患者:17例分化型甲状腺癌,5例未分化型甲状腺癌。
  • 主要终点为中心评估的客观缓解率,次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。

主要发现

  • 数据截止2022年10月26日,中位随访11.5个月(范围3.4-19.0个月)。
  • 中心评估客观缓解率为54.5%(95%CI 32.2-75.6),其中部分缓解12例,疾病稳定10例。
  • 分化型甲状腺癌客观缓解率为47.1%(17例中8例),未分化型甲状腺癌为80.0%(5例中4例)。
  • 总人群、分化型亚组和未分化型亚组的中位缓解持续时间、中心评估中位无进展生存期和中位总生存期均未达到。
  • 12个月时持续缓解率为90.9%,无进展生存率为78.8%,总生存率为81.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic thyroid cancer (ATC), in which BRAF inhibitors have shown clinical effectiveness. This Japanese phase 2 study evaluated the efficacy and safety of a BRAF inhibitor, encorafenib, combined with an MEK inhibitor, binimetinib, in patients with BRAF V600-mutated thyroid cancer. Methods: This phase 2, open-label, uncontrolled study was conducted at 10 institutions targeted patients with BRAF V600-mutated locally advanced or distant metastatic thyroid cancer not amenable to curative treatment who became refractory/intolerant to ≥1 previous vascular endothelial growth factor receptor-targeted regimen(s) or were considered ineligible for those. The primary endpoint was centrally assessed objective response rate (ORR). The secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Results: We enrolled 22 patients with BRAFV600E-mutated thyroid cancer: 17 had differentiated thyroid cancer (DTC), and 5 had ATC. At data cutoff (October 26, 2022), the median follow-up was 11.5 (range = 3.4-19.0) months. The primary endpoint of centrally assessed ORR was 54.5% (95% confidence interval [CI] 32.2-75.6; partial response in 12 patients and stable disease in 10). The ORRs in patients with DTC and ATC were 47.1% (8 of 17) and 80.0% (4 of 5), respectively. The medians for DOR and PFS by central assessment and for OS were not reached in the overall population, the DTC subgroup, or the ATC subgroup. At 12 months, the rate of ongoing response was 90.9%, and the PFS and OS rates were 78.8% and 81.8%, respectively. All patients developed ≥1 adverse events (AEs): grade 3 AEs in 6 patients (27.3%). No patients developed grade 4-5 AEs. The most common grade 3 AE was lipase increased (4 patients [18.2%]). Those toxicities were mostly manageable with appropriate monitoring and dose adjustment. Conclusions: Treatment with encorafenib plus binimetinib met the primary endpoint criteria and demonstrated clinical benefit in patients with BRAFV600E-mutated thyroid cancer regardless of its histological type, such as DTC or ATC, with no new safety concerns identified. Encorafenib plus binimetinib could thus be a new treatment option for BRAF V600-mutated thyroid cancer. Clinical Trial Registration number: Japan Registry of Clinical Trials: jRCT2011200018.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tahara M, Kiyota N, Imai H, et al. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan. Thyroid. 2024. PMID: 38343359. doi:10.1089/thy.2023.0547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。